Philip Tagari
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
Philip Tagari is the chief scientific officer at insitro, where he leads a team of multidisciplinary scientists and engineers focused on disease biology and approaches to speed the delivery of therapeutics. Before joining insitro, he spent a decade at Amgen as vice president of research in therapeutic discovery, where his teams advanced more than 30 molecules into clinical development and commercialization. Earlier in his career, he was a research fellow at Merck Frosst (Canada) Inc., contributed to the discovery of Singulair and Vioxx, and conducted research at McGill University, Oxford University, and the UK Medical Research Council. He is also noted by insitro for more than 30 years of research and preclinical development experience across areas including neurobiology, metabolic disease, hematology/oncology, immunology and inflammation, and biologics engineering.
Updated 19 October 2026
Public sources: insitro.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because Philip Tagari appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data